N-乙基亚丁基胺 | 1611-12-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-乙基亚丁基胺
• 英文名称: ethyl-butyliden-amine
• 英文别名: Butyraldehyd-aethylimin；Aethyl-butyliden-amin；N-Butyliden-ethylamin；1-Ethylimino-butan；Ethanamine, N-butylidene-；N-ethylbutan-1-imine
• CAS: 1611-12-7
• 化学式: C₆H₁₃N
• 分子量: 99.1759
• InChiKey: BLARBXSPVIJGSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  7
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2921199090

反应信息

• 作为反应物：
  描述：

  N-乙基亚丁基胺 在 乙醇 、 sodium 作用下， 生成 N-乙基正丁胺
  参考文献：
  名称：

  Tiollais, Bulletin de la Societe Chimique de France, 1947, p. 960

  摘要：

  DOI：
• 作为产物：
  描述：

  溴丁基-镁 、 1-nitrosoaziridine 以 乙醚 为溶剂， 生成 N-乙基亚丁基胺
  参考文献：
  名称：

  Rundel,W.; Mueller,E., Chemische Berichte, 1963, vol. 96, p. 2528 - 2531

  摘要：

  DOI：

文献信息

• Synthesis of novel isoquinoline derivatives as potential CNS-agents
  作者：B. Bonnaud、A. Carlessi、D. C. H. Bigg

  DOI：10.1002/jhet.5570300144

  日期：1993.1

  obtained by dipolar cycloaddition reactions of imines with homo-phthalic anhydride. Among the compounds tested 5c and 5m showed sub-micromolar affinity for the NMDA receptor and represent a structurally novel class of ligand for this site.

  制备了一系列的4-氨基甲基-1,2,3,4-四氢异喹啉衍生物作为潜在的CNS-试剂，通过氨基酸神经递质系统起作用。所述化合物由通过亚胺与高邻苯二甲酸酐的偶极环加成反应获得的1,2,3,4-四氢-1-氧代异喹啉-4-羧酸合成。在测试的化合物中，5c和5m对NMDA受体表现出亚微摩尔的亲和力，代表了该部位结构上新颖的一类配体。
• Réactivité des silyl- et germylphosphines vis-à-vis de divers composés à insaturation CN: imines, α-diimines, N-acylimines et cétènimines
  作者：Claude Couret、Françoise Couret、Jacques Satgé、Jean Escudié

  DOI：10.1002/hlca.19750580510

  日期：1975.7.16

  Silylphosphines R3SiPR′2 add on the CN group of aldimines yielding phosphinylated silylamines of the structure . Hydrolysis of these adducts leads to the corresponding substituted aminomethyl-phosphines.

  Silylphosphines - [R 3 SIPR' 2上的CN基醛亚胺，得到该结构的甲硅烷基胺phosphinylated添加。这些加合物的水解产生相应的取代的氨基甲基膦。
• Henze; Humphreys, Journal of the American Chemical Society, 1942, vol. 64, p. 2879,2880
  作者：Henze、Humphreys

  DOI：——

  日期：——
• Tiollais, Bulletin de la Societe Chimique de France, 1947, p. 713
  作者：Tiollais

  DOI：——

  日期：——
• Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria
  作者：George Jerums、Terri J. Allen、Duncan J. Campbell、Mark E. Cooper、Richard E. Gilbert、Jeremy J. Hammond、Jan Raffaele、Con Tsalamandris

  DOI：10.1016/s0272-6386(05)80003-4

  日期：2001.5

  The aim of this study is to compare the efficacy of an angiotensin-converting enzyme inhibitor with a dihydropyridine calcium channel blocker in preventing progression to macroalbuminuria and/or a decline in renal function in normotensive patients with type 1 diabetes and microalbuminuria. Forty-two patients were randomized to treatment with either perindopril, slow-release nifedipine, or placebo. In the first 3 months, drug dosage was titrated to achieve a decrease in diastolic blood pressure of at least 5 mm Hg. Thirty-three patients had a minimum of 24 months' data, and 25 patients were followed up beyond 36 months (mean, 67 +/- 4 months). Patients were studied every 3 months and at the end of the treatment period; those who remained normotensive discontinued therapy and were followed up for an additional 3 months. Baseline geometric mean albumin excretion rates (AERs) were as follows: perindopril, 66 mug/min; nifedipine, 59 mug/min; and placebo, 66 mug/min. During the first 3 years, 7 of the perindopril-treated but none of the placebo or nifedipine-treated patients reverted to normoalbuminuria (P < 0.01). Median AERs at 3 years of treatment in each group were 23 g/min for perindopril, 122 mug/min for nifedipine, and 112 mug/min for placebo patients (P < 0.01). in patients with more than 3 years' follow-up, median AERs decreased by 45% in the first year and then stabilized in the perindopril group, but increased by 17.6% in the nifedipine group and 27.6% in the placebo group (P < 0.03) in the first year, then increased progressively. In these same patients, there was a significant decline in glomerular filtration rate in the nifedipine group (-7.8 +/- 1.8 mL/min/1.73 m(2)/y), but not in the other two groups (perindopril, -1.0 +/- 1.2 mL/min/1.73 m(2)/y; placebo, -1.3 +/- 1.1 mL/min/1.73 m(2)/y; P = 0.004). At the end or the study, cessation of treatment for 3 months was associated with a doubling of AERs in the perindopril-treated group, but no change in the other two groups (P < 0.001). In conclusion, long-term perindopril therapy is more effective than nifedipine or placebo in delaying the progression of diabetic nephropathy and reducing AER to the normoalbuminuric range (<20 mug/min) in normotensive patients with type I diabetes and microalbuminuria. (C) 2000 by the National Kidney Foundation, Inc.

表征谱图